Retrospective In Silico Analysis of Routine Laboratory Data Supports a Specific Association of Epstein–Barr Virus and Multiple Sclerosis
European Journal of Neurology · 2025
DOI: 10.1111/ene.70430 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Neurology, 2025. Verfasst von Mario Rodomonti und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin,…. Hauptthemen laut MEDLINE: Multiple Sclerosis, Epstein-Barr Virus Infections, Herpesvirus 4, Human. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
We conducted a retrospective in silico analysis of routine laboratory data (RISAROLDA) to study the association of Epstein–Barr virus (EBV) and multiple sclerosis (MS).
Methods
Patients with MS and 10 different inflammatory/neoplastic diseases were identified by ICD10 codes. Results of routine laboratory testing for antibodies to EBV, measles, mumps, rubella, herpes simplex virus, varicella zoster virus and cytomegalovirus were extracted using a digital tool.
Results
Among 10,669 patients with MS and 42,222 controls, EBV serologies were available from 492 (4.6%) patients with MS and 1918 (4.5%) controls. While all but three patients with an ICD10 diagnosis of MS were EBV seropositive, closer inspection of the three EBV seronegative patients revealed they were misdiagnosed with MS, resulting in a 100% EBV seroprevalence in the remaining 489 patients with MS. In contrast, EBV seroprevalences were lower in all other diseases (78.6%–97.8%). Serum antibodies to the Epstein–Barr nuclear antigen‐1, but not to the viral capsid antigen, were higher in patients with MS than in all other diseases. In patients with MS, seroprevalences of all other common viruses were lower than those of EBV, but the frequency of intrathecal production of antibodies to EBV was lower than that of other common viruses.
Conclusions
These findings suggest that the association of EBV and MS is specific for MS as compared to various other inflammatory/neoplastic diseases and that a negative EBV serology might be a marker for the absence of MS. RISAROLDA is a powerful approach for the screening of real‐world laboratory data.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
- Labor Berlin-Charité Vivantes GmbH, Berlin, Germany.
- Department of Neuroscience, University of Padua, Padua, Italy.
- Division of Neuroimmunology, Department of Neurology, University of Heidelberg, Heidelberg, Germany.
ORCID-Profile: Rohat Geran, Klemens Ruprecht
Zitieren
APA
Rodomonti, M., Pache, F., Otto, C., Schindler, P., Eberspächer, B., Geran, R., Puthenparampil, M., Gallo, P., Wildemann, B., Jarius, S., Erdur, H., & Ruprecht, K. (2025). Retrospective In Silico Analysis of Routine Laboratory Data Supports a Specific Association of Epstein–Barr Virus and Multiple Sclerosis. European Journal of Neurology. https://doi.org/10.1111/ene.70430
Vancouver
Rodomonti M, Pache F, Otto C, Schindler P, Eberspächer B, Geran R, et al. Retrospective In Silico Analysis of Routine Laboratory Data Supports a Specific Association of Epstein–Barr Virus and Multiple Sclerosis. European Journal of Neurology. 2025. doi:10.1111/ene.70430
BibTeX
@article{Rodomonti2025,
author = {Rodomonti, Mario and Pache, Florence and Otto, Carolin and Schindler, Patrick and Eberspächer, Bettina and Geran, Rohat and Puthenparampil, Marco and Gallo, Paolo and Wildemann, Brigitte and Jarius, Sven and Erdur, Hebun and Ruprecht, Klemens},
title = {Retrospective In Silico Analysis of Routine Laboratory Data Supports a Specific Association of Epstein–Barr Virus and Multiple Sclerosis},
journal = {European Journal of Neurology},
year = {2025},
doi = {10.1111/ene.70430}
}
EUVIMED